Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 309

2.

Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.

Maxwell PJ, Coulter J, Walker SM, McKechnie M, Neisen J, McCabe N, Kennedy RD, Salto-Tellez M, Albanese C, Waugh DJ.

Eur Urol. 2013 Aug;64(2):177-88. doi: 10.1016/j.eururo.2012.08.032. Epub 2012 Aug 28.

3.

CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer.

Matsuo Y, Ochi N, Sawai H, Yasuda A, Takahashi H, Funahashi H, Takeyama H, Tong Z, Guha S.

Int J Cancer. 2009 Feb 15;124(4):853-61. doi: 10.1002/ijc.24040.

4.

Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2.

Ringe J, Strassburg S, Neumann K, Endres M, Notter M, Burmester GR, Kaps C, Sittinger M.

J Cell Biochem. 2007 May 1;101(1):135-46.

PMID:
17295203
5.

Constitutive and treatment-induced CXCL8-signalling selectively modulates the efficacy of anti-metabolite therapeutics in metastatic prostate cancer.

Wilson C, Maxwell PJ, Longley DB, Wilson RH, Johnston PG, Waugh DJ.

PLoS One. 2012;7(5):e36545. doi: 10.1371/journal.pone.0036545. Epub 2012 May 9.

6.

PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.

Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML, Chinni SR.

Mol Cancer. 2013 Jul 31;12(1):85. doi: 10.1186/1476-4598-12-85.

7.

Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events.

Gouwy M, Struyf S, Noppen S, Schutyser E, Springael JY, Parmentier M, Proost P, Van Damme J.

Mol Pharmacol. 2008 Aug;74(2):485-95. doi: 10.1124/mol.108.045146. Epub 2008 May 9.

8.

Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.

Hsiao JJ, Ng BH, Smits MM, Wang J, Jasavala RJ, Martinez HD, Lee J, Alston JJ, Misonou H, Trimmer JS, Wright ME.

BMC Cancer. 2015 Mar 31;15:204. doi: 10.1186/s12885-015-1201-5.

9.

Multi-faceted roles for CXC-chemokines in prostate cancer progression.

Waugh DJ, Wilson C, Seaton A, Maxwell PJ.

Front Biosci. 2008 May 1;13:4595-604. Review.

PMID:
18508531
10.

SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis.

Uygur B, Wu WS.

Mol Cancer. 2011 Nov 10;10:139. doi: 10.1186/1476-4598-10-139.

11.

HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.

Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, Stratford IJ, Williams KJ, Johnston PG, Waugh DJ.

Oncogene. 2007 Nov 15;26(52):7333-45. Epub 2007 May 28.

PMID:
17533374
12.

CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.

Singh S, Singh UP, Grizzle WE, Lillard JW Jr.

Lab Invest. 2004 Dec;84(12):1666-76.

13.

Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.

Gabellini C, Trisciuoglio D, Desideri M, Candiloro A, Ragazzoni Y, Orlandi A, Zupi G, Del Bufalo D.

Eur J Cancer. 2009 Sep;45(14):2618-27. doi: 10.1016/j.ejca.2009.07.007. Epub 2009 Aug 13.

PMID:
19683430
14.

PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.

Armstrong CW, Maxwell PJ, Ong CW, Redmond KM, McCann C, Neisen J, Ward GA, Chessari G, Johnson C, Crawford NT, LaBonte MJ, Prise KM, Robson T, Salto-Tellez M, Longley DB, Waugh DJ.

Oncotarget. 2016 Feb 16;7(7):7885-98. doi: 10.18632/oncotarget.6955.

15.

G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.

Liu X, Peng J, Sun W, Yang S, Deng G, Li F, Cheng JW, Gordon JR.

Tohoku J Exp Med. 2012;228(2):147-56.

16.

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

Zhang J, Lu Y, Pienta KJ.

J Natl Cancer Inst. 2010 Apr 21;102(8):522-8. doi: 10.1093/jnci/djq044. Epub 2010 Mar 16. Review.

17.

Interleukin-8 Induces Expression of FOXC1 to Promote Transactivation of CXCR1 and CCL2 in Hepatocellular Carcinoma Cell Lines and Formation of Metastases in Mice.

Huang W, Chen Z, Zhang L, Tian D, Wang D, Fan D, Wu K, Xia L.

Gastroenterology. 2015 Oct;149(4):1053-67.e14. doi: 10.1053/j.gastro.2015.05.058. Epub 2015 Jun 9.

PMID:
26065367
18.

Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells.

Chetram MA, Odero-Marah V, Hinton CV.

Mol Cancer Res. 2011 Jan;9(1):90-102. doi: 10.1158/1541-7786.MCR-10-0235. Epub 2010 Nov 12.

19.

IL-33 enhances proliferation and invasiveness of decidual stromal cells by up-regulation of CCL2/CCR2 via NF-κB and ERK1/2 signaling.

Hu WT, Li MQ, Liu W, Jin LP, Li DJ, Zhu XY.

Mol Hum Reprod. 2014 Apr;20(4):358-72. doi: 10.1093/molehr/gat094. Epub 2013 Dec 15.

PMID:
24344240
20.

Supplemental Content

Support Center